AAPL   321.87 (+0.01%)
MSFT   183.90 (+0.59%)
GOOGL   1,433.10 (-0.12%)
AMZN   2,466.62 (-0.18%)
BABA   213.64 (+3.42%)
TSLA   884.14 (-1.55%)
AMD   53.21 (-0.78%)
T   30.81 (-0.39%)
GILD   73.17 (-2.65%)
NFLX   426.39 (+0.11%)
BAC   24.71 (+0.37%)
AAPL   321.87 (+0.01%)
MSFT   183.90 (+0.59%)
GOOGL   1,433.10 (-0.12%)
AMZN   2,466.62 (-0.18%)
BABA   213.64 (+3.42%)
TSLA   884.14 (-1.55%)
AMD   53.21 (-0.78%)
T   30.81 (-0.39%)
GILD   73.17 (-2.65%)
NFLX   426.39 (+0.11%)
BAC   24.71 (+0.37%)
AAPL   321.87 (+0.01%)
MSFT   183.90 (+0.59%)
GOOGL   1,433.10 (-0.12%)
AMZN   2,466.62 (-0.18%)
BABA   213.64 (+3.42%)
TSLA   884.14 (-1.55%)
AMD   53.21 (-0.78%)
T   30.81 (-0.39%)
GILD   73.17 (-2.65%)
NFLX   426.39 (+0.11%)
BAC   24.71 (+0.37%)
AAPL   321.87 (+0.01%)
MSFT   183.90 (+0.59%)
GOOGL   1,433.10 (-0.12%)
AMZN   2,466.62 (-0.18%)
BABA   213.64 (+3.42%)
TSLA   884.14 (-1.55%)
AMD   53.21 (-0.78%)
T   30.81 (-0.39%)
GILD   73.17 (-2.65%)
NFLX   426.39 (+0.11%)
BAC   24.71 (+0.37%)
Log in

NASDAQ:FTSVForty Seven Stock Price, Forecast & News

$95.51
0.00 (0.00 %)
(As of 04/7/2020)
Add
Compare
Today's Range
$95.51
Now: $95.51
$95.51
50-Day Range
$95.51
MA: $95.51
$95.51
52-Week Range
$5.53
Now: $95.51
$95.51
VolumeN/A
Average Volume1.61 million shs
Market Capitalization$4.60 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.4
Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.
Read More
Forty Seven logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.2Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.16 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FTSV
CUSIPN/A
CIKN/A
Phone650-352-4150

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.68 million
Book Value$7.52 per share

Profitability

Net Income$-87,620,000.00

Miscellaneous

Employees57
Market Cap$4.60 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive FTSV News and Ratings via Email

Sign-up to receive the latest news and ratings for FTSV and its competitors with MarketBeat's FREE daily newsletter.

Forty Seven (NASDAQ:FTSV) Frequently Asked Questions

How has Forty Seven's stock been impacted by COVID-19 (Coronavirus)?

Forty Seven's stock was trading at $94.66 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, FTSV stock has increased by 0.9% and is now trading at $95.51. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Forty Seven?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Forty Seven in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Forty Seven.

How were Forty Seven's earnings last quarter?

Forty Seven Inc (NASDAQ:FTSV) announced its earnings results on Friday, March, 20th. The company reported ($0.55) EPS for the quarter, beating the Zacks' consensus estimate of ($0.70) by $0.15. View Forty Seven's earnings history.

What price target have analysts set for FTSV?

11 brokers have issued twelve-month target prices for Forty Seven's stock. Their forecasts range from $18.00 to $95.50. On average, they expect Forty Seven's stock price to reach $65.95 in the next year. This suggests that the stock has a possible downside of 30.9%. View analysts' price targets for Forty Seven.

What are Wall Street analysts saying about Forty Seven stock?

Here are some recent quotes from research analysts about Forty Seven stock:
  • 1. According to Zacks Investment Research, "Forty Seven, Inc. is a clinical-stage immuno-oncology company. It focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The company's product candidate consists of 5F9, is an IgG4 monoclonal antibody against CD47 which is designed to interfere with recognition of CD47 by the SIRP? receptor on macrophages. Forty Seven, Inc. is based in CA, United States. " (3/27/2020)
  • 2. Mizuho analysts commented, "We initiate coverage of FTSV with a Buy rating and $18 PT. We like the speed- to-market program for 5F9 (pivotal readout by 4Q20). We also like the pursuit of a novel mechanism in immuno-oncology, innate immunity via CD47. FTSV has cash into 2021 and readouts that should serve as valuation inflection points." (9/11/2019)

Has Forty Seven been receiving favorable news coverage?

Media stories about FTSV stock have trended positive this week, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Forty Seven earned a media sentiment score of 2.6 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutForty Seven.

Who are some of Forty Seven's key competitors?

What other stocks do shareholders of Forty Seven own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Forty Seven investors own include Sorrento Therapeutics (SRNE), Energy Transfer LP Unit (ET), TG Therapeutics (TGTX), NVIDIA (NVDA), Amarin (AMRN), GlycoMimetics (GLYC), Trillium Therapeutics (TRIL), AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD) and Clovis Oncology (CLVS).

Who are Forty Seven's key executives?

Forty Seven's management team includes the following people:
  • Dr. Mark A. McCamish, Pres, CEO & Director (Age 66)
  • Dr. Craig S. Gibbs, Chief Bus. Officer (Age 56)
  • Dr. Chris H. Takimoto M.D., Ph.D., Chief Medical Officer (Age 60)
  • Mr. Mark Chao, Founder & VP of Clinical Devel.
  • Mr. Jens-Peter Volkmer, Founder and VP of Research & Early Devel.

When did Forty Seven IPO?

(FTSV) raised $100 million in an IPO on Thursday, June 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity, BTIG and Oppenheimer were co-managers.

What is Forty Seven's stock symbol?

Forty Seven trades on the NASDAQ under the ticker symbol "FTSV."

Who are Forty Seven's major shareholders?

Forty Seven's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.82%), Wellington Management Group LLP (4.38%), Pentwater Capital Management LP (3.10%), JPMorgan Chase & Co. (3.03%), Beryl Capital Management LLC (2.33%) and Magnetar Financial LLC (1.77%). Company insiders that own Forty Seven stock include Ann D Rhoads, Chris H Takimoto, Christopher J Schaepe, Irving Weissman, Jeffrey W Bird, Lifesciences Iii LP Clarus, Lightspeed Venture Partners X,, Mark Anthony Mccamish, Peter Nieh, Ravi Mhatre, Ravindra Majeti and Stefan A Dyckerhoff. View institutional ownership trends for Forty Seven.

Which major investors are selling Forty Seven stock?

FTSV stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Healthcare of Ontario Pension Plan Trust Fund, Lord Abbett & CO. LLC, Parametric Portfolio Associates LLC, Bank of New York Mellon Corp, Schroder Investment Management Group, Deutsche Bank AG, and Rock Springs Capital Management LP. Company insiders that have sold Forty Seven company stock in the last year include Ann D Rhoads, Chris H Takimoto, Irving Weissman, Mark Anthony Mccamish, and Ravindra Majeti. View insider buying and selling activity for Forty Seven.

Which major investors are buying Forty Seven stock?

FTSV stock was bought by a variety of institutional investors in the last quarter, including Pentwater Capital Management LP, JPMorgan Chase & Co., Beryl Capital Management LLC, Magnetar Financial LLC, Alpine Associates Management Inc., Glazer Capital LLC, ARP Americas LP, and CNH Partners LLC. Company insiders that have bought Forty Seven stock in the last two years include Christopher J Schaepe, Jeffrey W Bird, Lifesciences Iii LP Clarus, Lightspeed Venture Partners X,, Peter Nieh, Ravi Mhatre, and Stefan A Dyckerhoff. View insider buying and selling activity for Forty Seven.

How do I buy shares of Forty Seven?

Shares of FTSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Forty Seven's stock price today?

One share of FTSV stock can currently be purchased for approximately $95.51.

How big of a company is Forty Seven?

Forty Seven has a market capitalization of $4.60 billion and generates $15.68 million in revenue each year. The company earns $-87,620,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. Forty Seven employs 57 workers across the globe.

What is Forty Seven's official website?

The official website for Forty Seven is www.fortyseveninc.com.

How can I contact Forty Seven?

Forty Seven's mailing address is 1490 O`BRIEN DRIVE SUITE A, MENLO PARK CA, 94025. The company can be reached via phone at 650-352-4150 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.